MTNB — Matinas BioPharma Holdings Balance Sheet
0.000.00%
Last trade - 00:00
- $44.87m
- $31.14m
- $1.10m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 27.8 | 58.7 | 49.6 | 28.8 | 13.8 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 29.9 | 61.6 | 51 | 34.5 | 15.5 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5.63 | 4.86 | 5.78 | 5.73 | 5.01 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 40.2 | 71 | 61.3 | 44.8 | 25.1 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.1 | 3.57 | 4.35 | 4.29 | 2.62 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 7.19 | 7.24 | 8.83 | 8.18 | 5.86 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 33.1 | 63.7 | 52.5 | 36.6 | 19.2 |
Total Liabilities & Shareholders' Equity | 40.2 | 71 | 61.3 | 44.8 | 25.1 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |